Abstract

Soria A, et al. Background: Combined BRAF/MEK inhibitors have demonstrated efficacy and tolerability in phase…

Schadendorf  D, et al. Background: In the randomized, 2-part, multicenter, open-label, phase III COLUMBUS study,…

Truong TG, et al. Background: Many patients with BRAF+ metastatic melanoma (MM) experience tumor progression…

In GK, et al. Background: ENCO+BINI, a combination BRAF and MEK inhibitor therapy, prolonged OS…

Hoeijmakers L, et al. Background: IMPemBra was the first trial testing intermittent, short-term, dabrafenib and…

Gupta A, et al. Background: BRAF+MEK inhibitors extend life expectancy of BRAF V600 mutant advanced…

Onofrio L, et al. Background: Among the most common causes of death in patients with…

Vitale M, et al. Background: Cancer patients (pts) with autoimmune diseases have been excluded from…

Cerro M, et al. Background: BRAF V600 mutations occur in 50% of cutaneous melanoma patients…

Buriolla S, et al. Background: The administration of SACT in the last month of life…